| Dr Andrea Ramirez Lightle, DO | |
|
47 New Scotland Ave Rm F117, Albany, NY 12208 | |
| (518) 262-4029 | |
| Not Available |
| Full Name | Dr Andrea Ramirez Lightle |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 12 Years |
| Location | 47 New Scotland Ave Rm F117, Albany, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891052056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 290462 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Albany Medical Center Hospital | Albany, NY | Hospital |
| Columbia Memorial Hospital | Hudson, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Albany Medical College | 1759293111 | 910 |
News Archive
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.
› Verified 1 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548290455 PECOS PAC ID: 1759293111 Enrollment ID: O20040309001433 |
News Archive
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.
› Verified 1 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124486329 PECOS PAC ID: 1759293111 Enrollment ID: O20160413000300 |
News Archive
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.
› Verified 1 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497921688 PECOS PAC ID: 1759293111 Enrollment ID: O20190320001621 |
News Archive
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrea Ramirez Lightle, DO 47 New Scotland Ave Rm F117, Albany, NY 12208-3412 Ph: () - | Dr Andrea Ramirez Lightle, DO 47 New Scotland Ave Rm F117, Albany, NY 12208 Ph: (518) 262-4029 |
News Archive
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.
› Verified 1 days ago
Dr. Syed Mohsin Ali Gilani, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave # Mc-81, Albany, NY 12208 Phone: 518-262-3661 | |
Julie Youngs, MD Pathology Medicare: Medicare Enrolled Practice Location: 43 New Scotland Ave # F117, Albany, NY 12208 Phone: 518-262-0463 | |
Dr. Bradley Gornstein, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, St. Peter's Hospital, Albany, NY 12208 Phone: 518-525-1550 | |
Dr. Russel E Newkirk, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 315 S Manning Blvd, Maplewood Pathology, Albany, NY 12208 Phone: 518-525-1474 | |
Dr. Jeffrey D Hubbard, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 315 S Manning Blvd, Maplewood Pathology, Albany, NY 12208 Phone: 518-525-1474 | |
Llewellyn Foulke, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave, Albany, NY 12208 Phone: 518-262-3738 | |
Tipu Nazeer, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave, Albany, NY 12208 Phone: 518-262-3738 |